Suppr超能文献

全球卒中流行病学和急性缺血性卒中干预措施的可及性。

Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions.

机构信息

From the Departments of Neurology (V.S., L.G., D.R.Y.) and Neurosurgery (V.S., D.R.Y.), Jackson Memorial Hospital and University of Miami Miller School of Medicine, FL.

出版信息

Neurology. 2021 Nov 16;97(20 Suppl 2):S6-S16. doi: 10.1212/WNL.0000000000012781.

Abstract

PURPOSE OF THE REVIEW

To provide an up-to-date review of the incidence of stroke and large vessel occlusion (LVO) around the globe, as well as the eligibility and access to IV thrombolysis (IVT) and mechanical thrombectomy (MT) worldwide.

RECENT FINDINGS

Randomized clinical trials have established MT with or without IVT as the usual care for patients with LVO stroke for up to 24 hours from symptom onset. Eligibility for IVT has extended beyond 4.5 hours based on permissible imaging criteria. With these advances in the last 5 years, there has been a notable increase in the population of patients eligible for acute stroke interventions. However, access to acute stroke care and utilization of MT or IVT is lagging in these patients.

SUMMARY

Stroke is the second leading cause of both disability and death worldwide, with the highest burden of the disease shared by low- and middle-income countries. In 2016, there were 13.7 million new incident strokes globally; ≈87% of these were ischemic strokes and by conservative estimation about 10%-20% of these account for LVO. Fewer than 5% of patients with acute ischemic stroke received IVT globally in the eligible therapeutic time window and fewer than 100,000 MTs were performed worldwide in 2016. This highlights the large gap among eligible patients and the low utilization rates of these advances across the globe. Multiple global initiatives are underway to investigate interventions to improve systems of care and bridge this gap.

摘要

目的

提供全球范围内卒中及大血管闭塞(LVO)发病率的最新综述,以及全球接受 IV 溶栓(IVT)和机械取栓(MT)治疗的适应证和机会。

最新发现

随机临床试验已经确立了 MT 联合或不联合 IVT 作为 LVO 卒中患者的标准治疗方法,发病后时间窗可达 24 小时。基于可接受的影像学标准,IVT 的适应证已经扩展到 4.5 小时以上。在过去 5 年中,由于这些进展,有更多的患者适合接受急性卒中干预。然而,这些患者的急性卒中治疗的机会和 MT 或 IVT 的应用仍存在不足。

总结

卒中是全世界导致残疾和死亡的第二大原因,低收入和中等收入国家的疾病负担最高。2016 年,全球新发卒中病例 1370 万例;其中约 87%为缺血性卒中,据保守估计,其中 10%-20%为 LVO。在全球范围内,只有不到 5%的急性缺血性卒中患者在可治疗的时间窗内接受 IVT,2016 年全球仅进行了不到 10 万例 MT。这突出了在适合治疗的患者中存在的巨大差距,以及这些进展在全球范围内的利用率低。多个全球性倡议正在进行中,以调查改善护理系统的干预措施,并弥合这一差距。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验